Aparicio, A., Tidwell, R. S., Basu, S., He, Z., Zurita, A. J., Siddiqui, B. A., Subudhi, S. K., Corn, P. G., Kovitz, C. A., Jana, B., Hahn, A. W., Alhalabi, O., Sheth, R., Deinert, J., Logothetis, C., Soundararajan, R., Thompson, T. C., Sharma, P., PiliƩ, P. G. (2025). C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5008